To hear about similar clinical trials, please enter your email below
Trial Title:
Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma
NCT ID:
NCT05934045
Condition:
ALK-Positive Anaplastic Large Cell Lymphoma
Conditions: Official terms:
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, Large-Cell, Anaplastic
Conditions: Keywords:
cancer
Study type:
Observational
Overall status:
Active, not recruiting
Study design:
Time perspective:
Retrospective
Intervention:
Intervention type:
Biological
Intervention name:
RNAseq
Description:
there is no intervention done.
Arm group label:
ALCL patient samples (serum)
Summary:
The objective of thE project is to determine, whether circRNAs could be used as
circulating prognostic and/or predictive biomarkers of ALK+ ALCL resistance to treatment
and whether they can be exploited as therapeutic targets.
Detailed description:
Anaplastic large-cell lymphoma (ALCL) is an aggressive T-cell pediatric lymphoma. 85% of
ALK+ ALCL cases harbor a fusion between the nucleophosmin (NPM) and anaplastic lymphoma
kinase (ALK) genes, leading to a constitutively activated and oncogenic fusion protein.
Most ALK+ ALCL cases initially respond well to the frontline chemotherapy, but 30% of
patients relapse and are of poor prognosis. Understanding the origins of therapy
resistance is of major importance to improve treatment and patient prognosis. Current
research highlights deregulated expression of regulatory non-coding RNAs (ncRNAs) as an
important factor in therapy resistance. To date, microRNAs and long noncoding RNAs have
been linked to therapy resistance in ALK+ ALCL. Circular RNAs (circRNAs) are a class of
highly stable noncoding RNAs that have recently come into the focus of researchers.
circRNAs can control target gene expression by e.g. interacting with microRNAs or
proteins. This project aims to elucidate their role in ALK+ ALCL biology including their
impact on noncoding RNA networks and therapy resistance. This project will (1) identify a
signature of circRNAs associated with therapy resistance in ALK+ ALCL, (2) analyze their
effect on treatment response, (3) elucidate their mechanism of action, and (4) evaluate
circRNA candidates as predictive and prognostic plasma biomarkers using liquid biopsies.
The goal of the study is to characterize the role of candidate circRNAs in this
well-defined cancer type, which can serve as a model for other ALK+ cancers. Project
results will add to the current mechanistic understanding of ALK+ ALCL pathogenesis and
the origins of therapy resistance, and could define new druggable targets and associated
predictive biomarkers for high-risk disease. Establishing the blood-based alternative
confirmation for the ALK+ ALCL diagnosis could also produce a less invasive predictive
tool capable of longitudinal patient monitoring for early relapse detection.
Criteria for eligibility:
Study pop:
patient at diagnosis of ALK+ ALCL, patient at the time of relapse for ALK+ ALCL, patient
without ALK+ ALCL
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- patient at diagnosis of ALK+ ALCL
- patient at the time of relapse for ALK+ ALCL
- patient without ALK+ ALCL
Exclusion Criteria:
-
Gender:
All
Minimum age:
18 Years
Maximum age:
99 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
IUCT-Oncopole University Hospital
Address:
City:
Toulouse
Zip:
31500
Country:
France
Start date:
January 1, 2023
Completion date:
December 31, 2025
Lead sponsor:
Agency:
University Hospital, Toulouse
Agency class:
Other
Collaborator:
Agency:
Institut National de la Santé Et de la Recherche Médicale, France
Agency class:
Other
Source:
University Hospital, Toulouse
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05934045
